Imperial College London
Professor Robert Wilkinson

ProfessorRobertWilkinson

Faculty of Medicine, Department of Infectious Disease

Professor in Infectious Diseases
 
 
 
//

Contact

 

r.j.wilkinson Website

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Davis:2021:10.12688/wellcomeopenres.16474.2,
author = {Davis, A and Donovan, J and Bremer, M and Van, Toorn R and Schoeman, J and Dadabhoy, A and Lai, RPJ and Cresswell, F and Boulware, D and Wilkinson, R and Thuong, NTT and Thwaites, G and Bahr, N and Tuberculous, Meningitis International Research Consortium},
doi = {10.12688/wellcomeopenres.16474.2},
journal = {Wellcome Open Research},
title = {Host directed therapies for tuberculous meningitis [version 2; peer review: 1 approved, 1 approved with reservations]},
url = {http://dx.doi.org/10.12688/wellcomeopenres.16474.2},
volume = {5},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - A dysregulated host immune response significantly contributes to morbidity and mortality in tuberculous meningitis (TBM). Effective host directed therapies (HDTs) are critical to improve survival and clinical outcomes. Currently only one HDT, dexamethasone, is proven to improve mortality. However, there is no evidence dexamethasone reduces morbidity, how it reduces mortality is uncertain, and it has no proven benefit in HIV co-infected individuals. Further research on these aspects of its use, as well as alternative HDTs such as aspirin, thalidomide and other immunomodulatory drugs is needed. Based on new knowledge from pathogenesis studies, repurposed therapeutics which act upon small molecule drug targets may also have a role in TBM. Here we review existing literature investigating HDTs in TBM, and propose new rationale for the use of novel and repurposed drugs. We also discuss host variable responses and evidence to support a personalised approach to HDTs in TBM.
AU  - Davis,A
AU  - Donovan,J
AU  - Bremer,M
AU  - Van,Toorn R
AU  - Schoeman,J
AU  - Dadabhoy,A
AU  - Lai,RPJ
AU  - Cresswell,F
AU  - Boulware,D
AU  - Wilkinson,R
AU  - Thuong,NTT
AU  - Thwaites,G
AU  - Bahr,N
AU  - Tuberculous,Meningitis International Research Consortium
DO  - 10.12688/wellcomeopenres.16474.2
PY  - 2021///
SN  - 2398-502X
TI  - Host directed therapies for tuberculous meningitis [version 2; peer review: 1 approved, 1 approved with reservations]
T2  - Wellcome Open Research
UR  - http://dx.doi.org/10.12688/wellcomeopenres.16474.2
UR  - http://hdl.handle.net/10044/1/91356
VL  - 5
ER  -
Download